Follow us on:

Avacta Group Excellent data for the first clinical evaluation of lateral flow antigen test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss first clinical evaluation of lateral flow antigen test. Alastair talks us through the data and explains the next steps in taking the test to market.

Share on:

Find more news, interviews, share price & company profile here for:Avacta Group Plc

Search

Other Interviews

Avacta Group geared up to bring high quality, high volume lateral flow antigen test to market (Interview) February 8, 2021
Avacta Group agreement with Astrea Bioseparations ‘the perfect deal’ (Interview) December 22, 2020
Avacta Group make significant progress with its highly scalable lateral flow test (Interview) November 23, 2020
Avacta Group a period of continued solid progress now looking to attract US investment (Interview) September 30, 2020
Avacta Group transfer technology to BBI Solutions for manufacture of COVID-19 test (Interview) August 7, 2020
Avacta Group rapid antigen test and affimer reagents that block the COVID-19 virus (Interview) June 25, 2020
Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview) May 20, 2020
Avacta Group CEO says ‘Substantial long term and sustainable value growth for shareholders’ (Interview) May 7, 2020
Avacta Group CEO Alastair Smith discusses COVID-19 antigen test (Interview) May 4, 2020
Avacta Group CEO Alastair Smith Looking to develop further COVID19 testing kit partnerships (Interview) April 24, 2020

More News

Avacta Group notice of results and investor presentation April 13, 2021
Avacta Group Win Diagnostic Licensing Deal with Biokit March 9, 2021
Avacta Group MHRA approves Clinical Trial & Excellent data from Lateral Flow Rapid Antigen Test February 24, 2021
Avacta Group Phase I Clinical Trial Approval by MHRA for AVA6000 February 18, 2021
Avacta Group SARS-CoV-2 lateral flow antigen test results show excellent performance February 16, 2021
Avacta Group announce commercial partnership with Mologi to accelerate CE marking of rapid antigen test February 8, 2021
Avacta Group secures AffyXell $7.3 Million Series A venture funding February 1, 2021
Avacta Group announce agreement with POINT Biopharma Inc. for pre|CISION™ technology January 7, 2021
Avacta Group submits application for AVA6000 Pro-doxorubixin trial December 23, 2020
Avacta Group significant progress made on SARS-CoV-2 rapid antigen test November 23, 2020